Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Gaush Meditech Ltd

高视医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

PROFIT WARNING

This announcement is made by Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rule 13.09(2)(a) of the Listing Rules.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the information currently available and a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended June 30, 2026, it is expected that the Group will record a net profit of approximately RMB13.9 million to RMB16.7 million for the six months ended June 30, 2026, as compared to a net profit of approximately RMB35.9 million for the six months ended June 30, 2025, representing a decrease by approximately 53.5% to 61.3%.

Based on the information currently available to the Board, the Board believes that the decrease in net profit was primarily attributable to:

(i) The revenue of the Group is expected to be approximately RMB541.5 million to RMB648.7 million for the six months ended June 30, 2026, representing a decrease by approximately 0.7% to 17.1% as compared to the revenue of approximately RMB653.1 million for the six months ended June 30, 2025. This is attributable to the combined impact of multiple adverse factors for the six months ended June 30, 2026, including shifts in market demand structure driven by national policies and the termination of the agency cooperation for overseas femtosecond laser-assisted cataract surgery products, which led to a decline in the Group's revenue from product distribution; and

(ii) Due to exchange rate fluctuations, foreign exchange losses for the six months ended June 30, 2026 are expected to increase by approximately RMB7.8 million to RMB9.8 million as compared to those for the six months ended June 30, 2025.

As of the date of this announcement, the Company is still in the process of finalizing the consolidated interim results of the Group for the six months ended June 30, 2026. The information contained in this announcement is based on a preliminary review of the unaudited consolidated management accounts of the Group and information currently available to the Board for the six months ended June 30, 2026, which has not been reviewed or audited by the auditors of the Company or reviewed by the audit committee of the Board. Shareholders and potential investors of the Company are advised to read carefully the interim results announcement of the Company for the six months ended June 30, 2026, which is expected to be published by the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, July 23, 2026

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Ms. Cheng Juan, Mr. Yubing Li and Ms. Qiu Xiaoling as independent non-executive Directors.